Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.

Summary

In matched real-world data of COPD patients with T2DM on single-inhaler triple therapy, GLP-1 receptor agonists were associated with lower risks of COPD exacerbation, pneumonia, oxygen dependence, and all-cause mortality versus DPP4 inhibitors, without excess serious GI events.

Key Findings

• GLP-1 analogue users had an 18% lower risk of COPD exacerbation (HR 0.82, 95% CI 0.71–0.94).
• Risks of pneumonia (HR 0.72) and oxygen dependence (HR 0.66) were significantly reduced.
• All-cause mortality was 40% lower with GLP-1 analogues (HR 0.60, 95% CI 0.47–0.77).
• No significant increase in serious gastrointestinal adverse events was observed.

Clinical Implications

For COPD patients with T2DM on SITT, GLP-1 receptor agonists may be preferable to DPP4 inhibitors to reduce exacerbations and mortality, warranting consideration in multidisciplinary COPD-diabetes management.

Limitations

• Observational design with potential residual confounding and confounding by indication
• Limited to COPD patients with T2DM on SITT; generalizability to broader COPD populations uncertain

Future Directions

Prospective trials examining GLP-1RA effects on COPD outcomes irrespective of diabetes status; mechanistic studies on pulmonary anti-inflammatory and infection-modulating pathways.